stockrowNeurocrine Biosciences, Inc. (NBIX) vs Zoetis Inc. (ZTS)
- Neurocrine Biosciences, Inc. NBIX 160.47 −3.36%
- Zoetis Inc. ZTS 81.72 −8.39%
Neurocrine Biosciences, Inc. and Zoetis Inc. are both Drug Manufacturers Specialty & Generic companies. Zoetis Inc. is the larger, with a market value of $33.9B against $16.2B — 2.1× the size. Zoetis Inc. trades at the lower P/E: 13.4× against 23.0×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 38.0% against 1.58%. Zoetis Inc. has the higher net margin (27.7% vs 19.0%) and the higher return on invested capital (19.6% vs 17.7%). Across the 22 metrics below, Zoetis Inc. leads on 13 and Neurocrine Biosciences, Inc. on 9.
Valuation
Profitability
| Metric | NBIX | ZTS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.75% | 71.67% | 53.51% |
| Operating margin | 23.96% | 37.13% | 0.00% |
| Net margin | 18.98% | 27.69% | (2.45%) |
| Free cash flow margin | 28.09% | 24.43% | 0.00% |
| Return on equity | 20.41% | 64.91% | (0.80%) |
| Return on assets | 14.20% | 17.84% | (1.67%) |
| Return on invested capital | 17.65% | 19.60% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack